| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/07/2023 | 176.77% | Cantor Fitzgerald | → $38 | Reiterates | → Overweight |
| 12/14/2022 | 111.22% | Stifel | → $29 | Initiates Coverage On | → Buy |
| 12/01/2022 | 82.08% | Goldman Sachs | → $25 | Initiates Coverage On | → Buy |
| 10/06/2022 | 133.07% | BTIG | → $32 | Initiates Coverage On | → Buy |
| 06/16/2021 | 264.17% | HC Wainwright & Co. | $40 → $50 | Maintains | Buy |
| 06/15/2021 | 118.5% | Piper Sandler | → $30 | Initiates Coverage On | → Overweight |
| 04/21/2021 | 191.33% | HC Wainwright & Co. | → $40 | Initiates Coverage On | → Buy |
| 03/04/2021 | 89.37% | SVB Leerink | $21 → $26 | Maintains | Outperform |
| 01/20/2021 | 52.95% | SVB Leerink | $4.5 → $21 | Maintains | Outperform |
| 10/23/2019 | — | SVB Leerink | Upgrades | Market Perform → Outperform | |
| 10/22/2019 | — | SVB Leerink | Upgrades | Market Perform → Outperform | |
| 09/06/2019 | — | JMP Securities | Downgrades | Market Outperform → Market Perform | |
| 08/09/2019 | -63.58% | Cantor Fitzgerald | $24 → $5 | Reiterates | → Overweight |
| 06/27/2019 | — | SVB Leerink | Downgrades | Outperform → Market Perform | |
| 05/06/2019 | — | SVB Leerink | Initiates Coverage On | → Outperform | |
| 10/16/2018 | 147.63% | JMP Securities | $47 → $34 | Maintains | Market Outperform |
| 03/28/2018 | 278.73% | Leerink Swann | $54 → $52 | Maintains | Outperform |
| 03/13/2018 | 293.3% | Leerink Swann | $56 → $54 | Maintains | Outperform |
| 02/09/2018 | 286.02% | Guggenheim | → $53 | Initiates Coverage On | → Buy |
What is the target price for Aclaris Therapeutics (ACRS)?
The latest price target for Aclaris Therapeutics (NASDAQ: ACRS) was reported by Cantor Fitzgerald on February 7, 2023. The analyst firm set a price target for $38.00 expecting ACRS to rise to within 12 months (a possible 176.77% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Aclaris Therapeutics (ACRS)?
The latest analyst rating for Aclaris Therapeutics (NASDAQ: ACRS) was provided by Cantor Fitzgerald, and Aclaris Therapeutics reiterated their overweight rating.
When is the next analyst rating going to be posted or updated for Aclaris Therapeutics (ACRS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aclaris Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aclaris Therapeutics was filed on February 7, 2023 so you should expect the next rating to be made available sometime around February 7, 2024.
Is the Analyst Rating Aclaris Therapeutics (ACRS) correct?
While ratings are subjective and will change, the latest Aclaris Therapeutics (ACRS) rating was a reiterated with a price target of $0.00 to $38.00. The current price Aclaris Therapeutics (ACRS) is trading at is $13.73, which is within the analyst's predicted range.